The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant interest within the British Isles, prompting a notable shift in peptide trends. Availability these treatments remains a complex challenge , with NHS coverage currently limited and private clinics offering treatment at a premium . Questions are bei